Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients.

@article{Molina2015EffectOE,
  title={Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients.},
  author={Beatriz D{\'i}az Molina and Elena Velasco Alonso and Jos{\'e} Luis Lambert Rodr{\'i}guez and M J Rodr{\'i}guez Bernardo and Jos{\'e} Rozado Casta{\~n}o and R Padr{\'o}n Encalada and Mar{\'i}a Antonia Mart{\'i}n Fern{\'a}ndez and F Pun Chinchai and Santiago Colunga Blanco and Ascension Garcia Campos},
  journal={Transplantation proceedings},
  year={2015},
  volume={47 1},
  pages={130-1}
}
INTRODUCTION Viral infections, especially cytomegalovirus (CMV), are a leading cause of early death and morbidity after heart transplantation. Several strategies have been used to minimize the risk, including universal prophylaxis with ganciclovir or valganciclovir and preemptive therapy. Lately, everolimus (EVE) efficacy studies have shown a protective effect against CMV infection. METHODS We studied retrospectively a series of 223 heart transplant patients, dividing them into 5 groups… CONTINUE READING